A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
A Tang, Z Chen, KS Cox, HP Su, C Callahan… - Nature …, 2019 - nature.com
Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant
mortality under six months of age worldwide; therefore, the prevention of RSV infection in all …
mortality under six months of age worldwide; therefore, the prevention of RSV infection in all …
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
MSA Gilman, CA Castellanos, M Chen… - Science …, 2016 - science.org
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in young
children and the elderly. There are currently no licensed RSV vaccines, and passive …
children and the elderly. There are currently no licensed RSV vaccines, and passive …
Infants infected with respiratory syncytial virus generate potent neutralizing antibodies that lack somatic hypermutation
E Goodwin, MSA Gilman, D Wrapp, M Chen… - Immunity, 2018 - cell.com
Respiratory syncytial virus (RSV) is a leading cause of infant mortality, and there are
currently no licensed vaccines to protect this vulnerable population. A comprehensive …
currently no licensed vaccines to protect this vulnerable population. A comprehensive …
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Q Zhu, JS McLellan, NL Kallewaard… - Science translational …, 2017 - science.org
Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health
priority. However, no vaccine is currently available to protect this vulnerable population …
priority. However, no vaccine is currently available to protect this vulnerable population …
Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies
HG Jones, T Ritschel, G Pascual, JPJ Brakenhoff… - PLoS …, 2018 - journals.plos.org
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
in infants and the elderly, and yet there remains no effective treatment or vaccine. The …
in infants and the elderly, and yet there remains no effective treatment or vaccine. The …
A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
Respiratory syncytial virus (RSV) remains a major human pathogen, infecting the majority of
infants before age two and causing re-infection throughout life. Despite decades of RSV …
infants before age two and causing re-infection throughout life. Despite decades of RSV …
Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein
D Tian, MB Battles, SM Moin, M Chen… - Nature …, 2017 - nature.com
A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive
prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated …
prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated …
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
B Ahani, KM Tuffy, AA Aksyuk, D Wilkins… - Nature …, 2023 - nature.com
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV)
fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical …
fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical …
Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
I Rossey, MSA Gilman, SC Kabeche, K Sedeyn… - Nature …, 2017 - nature.com
Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract
infections in young children. The RSV fusion protein (F) is highly conserved and is the only …
infections in young children. The RSV fusion protein (F) is highly conserved and is the only …
A phase 1 randomized, double‐blind, placebo‐controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing …
AO Aliprantis, D Wolford, L Caro… - Clinical …, 2021 - Wiley Online Library
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract
infection and related morbidity and mortality in infants. Passive immunization with an RSV …
infection and related morbidity and mortality in infants. Passive immunization with an RSV …